Read about public funding accelerating preclinical CRISPR gene-editing programs aimed at lipid drivers of cardiometabolic disease.
Key Takeaways
- CIRM awarded more than $25 million to advance two preclinical CRISPR programs
- STX-1200 is designed to lower lipoprotein(a) by targeting the LPA gene
- STX-1400 targets APOC3 to durably reduce triglyceride-rich lipoproteins and pancreatitis risk